KDR and hepatocellular carcinoma: Given the crucial role of Klotho/VEGFR2/PAK1 activation in hepatoma resistance to anoikis in hepatocarcinogenesis, specific inhibitors directing VEGFR2 or PAK1 including Sorafenib, Axitinib and IPA3 might prove useful as anoikis-sensitizing therapeutic drugs for intervention with HCC metastasis.